The ASX listing office in this one gets it wrong every time, and...

The ASX listing office in this one gets it wrong every time, and the companies misadventures with ASX procedures well illustrated.

This is however, getting back to the actual news, a rather promising natural regualtory pathway progression with Singapore’s leading public
sector R&D agency.

"The commencement of first-in-human clinical trials comes on the back of the signing of two non-binding term sheets on 14 April 2023 with Accelerate Technologies Pte Ltd (A*STAR)1 to commercialise groundbreaking technology that accelerates bone and tissue regeneration."

The A*Star collaboration was rather overlooked in importance by the mkt, when it was announced. Now its actually progressing the effects for the company massively amplified and the market plays catch up on importance of this, that the marker (ergo investors) forgot when they got lost in the doom and gloom of OSX's capital (mis)management antics, prospects of, this news provides assurance to going forward.